To provide an efficient comparison to pSi particles, Xenogenic Bone Substitute (XBS) particles already available on the market were used as the control. We used Bio-Oss® products that are commercially available bone granules of bovine origin (Bio-Oss®, Geistlich Pharma AG, Wolhusen, Switzerland), in which organic components have been removed without alteration of the microstructure and mineral part. Thus, these XBS particles harbor a structure and composition that resembles mineralized human bone.
Bio oss
Manufactured by Geistlich Pharma
Sourced in Switzerland, Germany, Italy, United States
Bio-Oss is a bone substitute material derived from bovine bone. It is a porous and natural mineral scaffold that provides a framework for new bone formation.
Automatically generated - may contain errors
Lab products found in correlation
Bio gide, by Geistlich Pharma (14 mentions)
Bio oss collagen, by Geistlich Pharma (2 mentions)
Saos 2, by American Type Culture Collection (1 mentions)
Polyglactin 910, by Johnson & Johnson (1 mentions)
Jsm 5600lv, by JEOL (1 mentions)
Su3500, by Hitachi (1 mentions)
4 0 vicryl, by Johnson & Johnson (1 mentions)
Zoletil 50, by Virbac (1 mentions)
Cary 630, by Agilent Technologies (1 mentions)
Ostim, by Kulzer (1 mentions)
Boneceramic, by Straumann (1 mentions)
Axiovision 4, by Zeiss (1 mentions)
60 protocols using bio oss
1
Xenogenic Bone Substitute Comparison
2
Buccal Defect Augmentation Protocols
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
The overall study flow was presented in Fig. 1 . A buccal dehiscence defect model50 (link) was constructed in order to simulate a damaged extraction socket (the experimental site). After inducing the dehiscence defect, the mesial roots of the mandibular second, third, and fourth premolars (P2, P3, and P4, respectively) were extracted 4 weeks later. Each distal root was subjected to root canal treatment after hemisection and was kept as a reference pristine site for the corresponding mesial root. The following two extraction sockets on the unilateral alveolar ridge were rotated into the following groups to produce an equal distribution of three other premolar sites:
DBBM/membrane group: ARP with DBBM (Bio-Oss®; Geistlich Pharma AG, Wolhusen, Switzerland) and a membrane (Bio-Gide®, Geistlich Pharma AG, Wolhusen, Switzerland)
DBBM/matrix group: ARP with DBBM (Bio-Oss®; Geistlich Pharma AG, Wolhusen, Switzerland) and a matrix (Collagen Graft 2®, Genoss, Suwon, Korea)
DBBM/membrane group: ARP with DBBM (Bio-Oss®; Geistlich Pharma AG, Wolhusen, Switzerland) and a membrane (Bio-Gide®, Geistlich Pharma AG, Wolhusen, Switzerland)
DBBM/matrix group: ARP with DBBM (Bio-Oss®; Geistlich Pharma AG, Wolhusen, Switzerland) and a matrix (Collagen Graft 2®, Genoss, Suwon, Korea)
3
Biomaterial Comparison for Bone Grafting
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
The following materials were used in the study; Bio-Oss® (BO) (Cat no: 20112, Geistlich Pharma, Switzerland), full-processed MoaBone® as supplied by the manufacturer (MB) (MOLTENO Ophthalmic Ltd., Dunedin, New Zealand), half-processed MoaBone (HP-MB) (degreased), batch no. 1810/SBE2 and heat-treated MB prepared from the HP-MB (HT-MB) as described in the next section.
4
Bone Regeneration with Hybrid Biomaterials
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
The Type A (TA) and Type B (TB) materials were prepared and provided by the School of Materials Science and Engineering of Tsinghua University and Beijing Allgens Medical Technology Co., Ltd., respectively. The TA material was a 7/3 mixture of HA and collagen, with a partially MC component. The TB material also had a HA/collagen ratio of 7/3 with MC. The nanosized HA was periodically and orderly arranged between collagen molecules, which self-assembled to form the basic structural units of the MC. Bio-Oss (BO), which is bovine bone calcined at high temperature, was purchased from Geistlich Pharma AG (Switzerland). It was free of all organic components and was used in the control group. The blank control (BC) group contained only bone defects with a collagen membrane (Bio-Gide; Geistlich), and did not contain any graft-filling material.
5
Biocompatible Bone Graft Carrier
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Deproteinized sterilized bovine bone, Bio-Oss® (Geistlich-Pharma, Wolhusen, Switzerland), with granules 0.25-1 mm in size (size S) was used for the implant construction. Due to its biocompatibility, osteoconductivity, highly interconnected pores, high surface area[24 (link)] and high structural similarity to hydroxyapatite in bone[25 ], this biomaterial is suitable as a carrier for growth factors and cells. In the present study, Bio-Oss® was used as a carrier for cells and growth factors and therefore labeled as BMM carrier.
6
Bone Substitute Material Evaluation
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
All cell culture media and reagents were purchased from Dominique Dutscher (Brumath, France). GTO® (GTO) and Gen-Os® (Gen-Os) of OsteoBiol® series for bone substitutes were obtained from Tecnoss® Dental s.r.l., Turin, Italy), and Geistlich Bio-Oss® (Bio-Oss) material was from Geistlich Pharma (Wolhusen, Switzerland).
7
Bovine Bone Graft Characteristics
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Bio-Oss (Geistlich Pharma AG, Wolhusen, Switzerland) was used as the xenogenic bone graft material. Its particle size ranged from 250 to 1000 μm in diameter. This material is sterilized bovine bone with all organic components removed.
8
Bone Graft Comparison with Autogenous
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Bone materials were mixed and used, and they were divided into two groups, containing autogenous bones and without autogenous bones. In the group containing autogenous bones (46 implants), the bone harvested from the maxillary tuberosity or the mandible symphysis was mixed with allogeneic bones such as Regenaform (Exactech, Gainesville, FL, USA) or xenogeneic bones such as Bio-Oss (Geistlich Pharma AG, Wolhusen, Switzerland) and grafted. In the group without autogenous bones (30 implants), allogeneic bones such as Regenaform were mixed with xenogeneic bones such as Bio-Oss and grafted.
9
Electron Beam Irradiation of Bone Samples
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
To prepare the electron beam-irradiated bone, we first obtained commercially available samples consisting of four allogenic bones, six xenogenic bones, and six synthetic bones. We used 1.0-MeV and 2.0-MeV linear accelerators (power 100 KW, pressure 115 kPa, temperature -30 to 120°C, sensor sensitivity: 0.1-1.2 m V/kPa, generating power sensitivity: 44.75 mV/kPa, supply voltage: 50.25 V), and a microtrone with different individual irradiation doses such as 60 kGy and 120 kGy.
The allogenic bone materials were Accell® (ISOTIS OrthogBiologics Inc., Irvine, USA), Allotis® (BioTis Bone Bank, Seoul, Korea), Oragraft® (LifeNet, Virginia Beach, VA, USA), and Orthoblast® (Integra Orthobiologics Inc., Irvine, USA). The xenogenic bone materials were BBP® (OscoTec Inc., Seongnam, Korea), Bio-cera® (OscoTec Inc., Seongnam, Korea), Bio-oss® (Geistlich Pharma AG, Wolhusen, Switzerland), Indu-cera® (OscoTec Inc., Seongnam, Korea), OCS-B® (Nibec Co., Seoul, Korea), and OCS-H® (Nibec Co., Seoul, Korea). The synthetic bone materials were BMP® (Cowellmedi Co., Seoul, Korea), BoneMedik® (Meta Biomed Co., Cheongju, Korea), Boneplus® (Megagen Co., Seoul, Korea), MBCP® (Biomatlante, vigneux de Bretagne, France), Osteon® (Genoss, Suwon, Korea), and Osteogen® (Impladent Ltd., Hollis, USA).
The allogenic bone materials were Accell® (ISOTIS OrthogBiologics Inc., Irvine, USA), Allotis® (BioTis Bone Bank, Seoul, Korea), Oragraft® (LifeNet, Virginia Beach, VA, USA), and Orthoblast® (Integra Orthobiologics Inc., Irvine, USA). The xenogenic bone materials were BBP® (OscoTec Inc., Seongnam, Korea), Bio-cera® (OscoTec Inc., Seongnam, Korea), Bio-oss® (Geistlich Pharma AG, Wolhusen, Switzerland), Indu-cera® (OscoTec Inc., Seongnam, Korea), OCS-B® (Nibec Co., Seoul, Korea), and OCS-H® (Nibec Co., Seoul, Korea). The synthetic bone materials were BMP® (Cowellmedi Co., Seoul, Korea), BoneMedik® (Meta Biomed Co., Cheongju, Korea), Boneplus® (Megagen Co., Seoul, Korea), MBCP® (Biomatlante, vigneux de Bretagne, France), Osteon® (Genoss, Suwon, Korea), and Osteogen® (Impladent Ltd., Hollis, USA).
10
Evaluation of Bone Graft Materials
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Allografts (OraGRAFT ® , LifeNet Health, VA, USA) (DO BONE ® , Biotem, Seongnam-si, Korea) , Xenograft (BioOss ® , Geistlich Pharma, Wolhausen, Switzerland), Alloplast (BoneCeramic ® , Straumann Holding, Basel, Switzerland). Human tooth and mandibular ramus bone that would be discarded as clinical waste (Table 1).
About PubCompare
Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.
We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.
However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.
Ready to get started?
Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required
Revolutionizing how scientists
search and build protocols!